CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.65
+1.37%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$9.73
From 52W high−62.19%
Volume820068.00
Market cap$811.77M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$9.73
From 52W high
−62.19%
Volume
820068.00
Market cap
$811.77M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.6x
P/E (TTM)
—
RSI (14)
32.1
MomentumView details →
1D Return
+1.37%
YTD Return
+25.56%
SummaryUpdated Jun 1, 2026
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Burlingame, California. The company went public in March 2016 and focuses on developing novel immuno-oncology and immunology therapies. Corvus specializes in targeting specific pathways that regulate immune system function, with particular expertise in developing small molecule inhibitors and monoclonal antibodies for cancer and autoimmune diseases.
Similar companies
Latest newsMore news →
Corvus Pharmaceuticals began enrollment in a Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.19d agoCorvus Pharmaceuticals announced the publication in Blood of final Phase 1 data from its soquelitinib Phase 1/1b T cell lymphoma trial, supporting ongoing registration trials.54d ago